JS
Jay Spiegel
University of Miami, Stanford University, Georgetown University School of Medicine, York University, University of Toronto
Research areas: Medicine · Oncology · CAR-T cell therapy research · Lymphoma Diagnosis and Treatment · T-cell and B-cell Immunology
0000-0001-6491-0044
Employment
-
University of Miami Assistant Professor2021 - Present
-
Stanford University Fellow2017 - 2021
-
University of Toronto Resident2014 - 2017
Education
-
Georgetown University School of Medicine MD2010 - 2014
-
York University Honors BSc2006 - 2010
Projects & Funding
Projects & funding information is unavailable.
Publications (20)
- Antigen levels in normal B cells and B-cell malignancies established by a multicolor quantitative flow cytometry assay Save
- False-positive HIV-1 RNA detection following obecabtagene autoleucel Save
- Mosunetuzumab and polatuzumab combined with axicabtagene ciloleucel induce high complete response rates at day+90 in Relapsed/Refractory large B-cell lymphoma Save
- Second Primary Cancer After Chimeric Antigen Receptor-T-Cell Therapy: A Review. Save
- Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium Save
- Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium Save
- Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium Save
- Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy Save
- Treating CAR-T relapses: check not checkmate Save
- Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial Save
- CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial Save
- CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR–refractory large B-cell lymphoma Save
- Molecular Imaging of Chimeric Antigen Receptor T Cells by ICOS-ImmunoPET Save
- Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma Save
- Outcomes of Patients with Large B-cell Lymphoma Progressing after Axicabtagene Ciloleucel Save
- Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium Save
- Clinical Utility of Next-generation Sequencing in the Management of Myeloproliferative Neoplasms: A Single-Center Experience Save
- A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies Save
- Impact of genomic alterations on outcomes in myelofibrosis patients undergoing JAK1/2 inhibitor therapy Save
- Validation of the NCCN-IPI in both de novo and transformed diffuse large B cell lymphoma Save